Eliem Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 22.29 million compared to USD 13.2 million a year ago. Basic loss per share from continuing operations was USD 0.84 compared to USD 0.5 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.46 USD | -5.45% | -0.90% | +184.44% |
12/06 | Eliem Therapeutics, Inc. Appoints Aoife Brennan as Chief Executive Officer | CI |
12/06 | Eliem Therapeutics, Inc. Announces Management Changes | CI |
1st Jan change | Capi. | |
---|---|---|
+184.44% | 235M | |
+16.44% | 122B | |
+20.12% | 115B | |
+21.22% | 26.64B | |
-23.35% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.86% | 15.49B | |
+61.75% | 14.83B | |
+3.35% | 13.67B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023